( s (p less than 0.0001 for both comparis...)AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain,Health

s (p less than 0.0001 for both comparisons), demonstrating significantly greater reductions in pain compared with placebo. Pain score averaged over the study periods were significantly lower than placebo in the DM/Q 45 arm for comparisons at days 30, 60 and 90 (p less than 0.0001 for each comparison) and in the DM/Q 30 arm (p less than 0.0001 at days 30 and 60, p=0.0071 at day 90). The consistency in the magnitude of response suggests that the pain reduction obtained with active treatment relative to placebo were maintained over the entire study duration.

-- Improvements from baseline with active treatment appeared to be dose dependent, with the higher dose resulting in improvements that were almost twice as great as placebo.

-- Both doses demonstrated significantly better improvements in pain from baseline that were maintained over the duration of the study.

-- The incidence of AEs was higher in the DM/Q 45 group (91%), compared with placebo (80%) and DM/Q 30 (79%), with the proportion of patients discontinuing due to an AE higher in both active treatments compared with placebo.

-- The most common AEs were dizziness, nausea, diarrhea, fatigue and somnolence and were generally mild to moderate in severity.

-- There were no statistically significant differences in serious adverse event rates reported in the DM/Q 45, DM/Q 30 and placebo groups, and no deaths occurred during the study.

Poster: "IMPROVED PATIENT-CENTERED OUTCOMES WITH DEXTROMETHORPHAN/ QUINIDINE VS PLACEBO IN A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL INVESTIGATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY," reports on the secondary efficacy endpoints in the Phase III study on outcomes of importance to patients, including pain relief, sleep and quality-of-life. Highlights include:

-- Both Zenvia doses were significantly superior to placebo in relieving pain. The pattern reported in the Pain Relief Scale complemented that shown by the Pai
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies